Real-World Experience with Approved CAR T-Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in 1272 Relapsed/Refractory Multiple Myeloma Patients - PubMed
7 hours ago
- #Multiple Myeloma
- #CAR T-cell therapy
- #Real-world evidence
- Study evaluates real-world outcomes of CAR T-cell therapies cilta-cel and ide-cel in 1272 relapsed/refractory multiple myeloma patients.
- Cilta-cel showed 12-month overall survival of 89.6% vs. 86.0% for ide-cel; renal impairment linked to inferior survival in both groups.
- Any-grade cytokine release syndrome occurred in 45.9% (cilta-cel) and 41.8% (ide-cel); severe neurotoxicity was rare (<3%).
- Hematologic toxicity was common, with grade ≥3 neutropenia in 76.0% (cilta-cel) and 68.0% (ide-cel).
- Infections and hypogammaglobulinemia were frequent, indicating long-term immunosuppressive burden, but survival benefits outweigh safety concerns.